Levin Rami reported option exercise involving 4,750 derivative units of CNS Pharmaceuticals, Inc. at $0.00 for $0 on Aug 14, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CEO and President
CEO and President
Filed Aug 18, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
4,750Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
14,250Direct
Trade date
Aug 14, 2026Option exercise
Filed
Aug 18, 2026, 9:00 AM ET4-day reporting delay
Accession
0001683168-26-006552Code M · Transaction 1563
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 14, 2026Option exercise4,750$0.00$0Trade 1562
2 transaction rows in this filing. Joint filers share the same rows.

CNSP price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CNSP · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −20%1w ago −8.2%1d ago −12%
Returns since7d +0.7%30d −6.1%90d180d1y

Footnotes in full

F1: Each restricted stock unit represents a contingent right to receive one share of Company common stock. F2: On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date. F3: Issued in connection with the reporting person's employment with the Company.